Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1981 1
1982 1
1985 1
1988 1
1990 1
1994 1
1995 2
1998 1
2000 1
2001 4
2002 3
2003 1
2004 2
2005 5
2006 2
2007 3
2008 2
2009 5
2010 1
2011 5
2012 7
2013 3
2014 6
2015 6
2016 6
2017 4
2018 9
2019 11
2020 23
2021 21
2022 14
2023 31
2024 31
2025 37
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6-110) was -2.7 mL/min per 1.73 m(2) per year versus -3.8 mL/min per 1.73 m(2) per year (difference 1.1 mL/min per 1.73 m(2 …
Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6-11 …
Atrasentan in Patients with IgA Nephropathy.
Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J; ALIGN Study Investigators. Heerspink HJL, et al. N Engl J Med. 2025 Feb 6;392(6):544-554. doi: 10.1056/NEJMoa2409415. Epub 2024 Oct 25. N Engl J Med. 2025. PMID: 39460694 Clinical Trial.
METHODS: We are conducting a phase 3, multinational, double-blind, randomized, controlled trial involving adults with biopsy-proven IgA nephropathy, a total urinary protein excretion of at least 1 g per day, and an estimated glomerular filtration rate of at least 30 ml per minute …
METHODS: We are conducting a phase 3, multinational, double-blind, randomized, controlled trial involving adults with biopsy-proven IgA neph …
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Fervenza FC, et al. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427. N Engl J Med. 2019. PMID: 31269364 Clinical Trial.
METHODS: We randomly assigned patients who had membranous nephropathy, proteinuria of at least 5 g per 24 hours, and a quantified creatinine clearance of at least 40 ml per minute per 1.73 m(2) of body-surface area and had been receiving angiotensin-system blockade for at …
METHODS: We randomly assigned patients who had membranous nephropathy, proteinuria of at least 5 g per 24 hours, and a quantified creatinine …
Iptacopan in IgA Nephropathy - Final 24-Month Data.
Barratt J, Eren N, Kashihara N, Maes B, Rizk DV, Rovin B, Trimarchi H, Zhang H, Wang W, Kocyigit I, Hao C, Tesař V, Turgutalp K, Yang L, Xing G, Duro Garcia V, Han SH, Lu W, Pisani A, Weinmann-Menke J, Eitner F, Guerard N, Butylin D, Monaco L, Scosyrev E, Magirr A, Renfurm R, Hach T, Perkovic V; APPLAUSE-IgAN Study Group. Barratt J, et al. N Engl J Med. 2026 Jul 30;395(5):465-477. doi: 10.1056/NEJMoa2600743. Epub 2026 Mar 29. N Engl J Med. 2026. PMID: 41910396 Clinical Trial.
Secondary end points included a composite kidney-failure end point (i.e., a sustained decline in eGFR of 30%, a sustained eGFR of <15 ml per minute per 1.73 m(2), the initiation of maintenance dialysis, receipt of kidney transplant, or death from kidney failure), asses …
Secondary end points included a composite kidney-failure end point (i.e., a sustained decline in eGFR of 30%, a sustained eGFR of <15 ml …
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. Mathur M, et al. N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2. N Engl J Med. 2024. PMID: 37916620 Free PMC article. Clinical Trial.
At 12 months, the least-squares mean ( SE) change from baseline in eGFR was -2.7 1.8, 0.2 1.7, -1.5 1.8, and -7.4 1.8 ml per minute per 1.73 m(2) in the sibeprenlimab 2-mg, 4-mg, and 8-mg groups and the placebo group, respectively. ...
At 12 months, the least-squares mean ( SE) change from baseline in eGFR was -2.7 1.8, 0.2 1.7, -1.5 1.8, and -7.4 1.8 ml per minute per 1.73 …
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J. Zhang H, et al. Kidney Int. 2024 Jan;105(1):189-199. doi: 10.1016/j.kint.2023.09.027. Epub 2023 Oct 31. Kidney Int. 2024. PMID: 37914086 Free article. Clinical Trial.
Our randomized, double-blind, parallel-group adaptive Phase 2 study (NCT03373461) enrolled patients with biopsy-confirmed IgAN (within previous three years) with estimated glomerular filtration rates of 30 mL/min/1.73 m(2) and over and urine protein 0.75 g/24 hours and ove …
Our randomized, double-blind, parallel-group adaptive Phase 2 study (NCT03373461) enrolled patients with biopsy-confirmed IgAN (within previ …
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
At nine months, UPCR was 27% lower in the Nefecon group compared with placebo, along with a benefit in eGFR preservation corresponding to a 3.87 ml/min/1.73 m(2) difference versus placebo (both significant). Nefecon was well-tolerated, and treatment-emergent adverse events …
At nine months, UPCR was 27% lower in the Nefecon group compared with placebo, along with a benefit in eGFR preservation corresponding to a …
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Heerspink HJL, Jardine MJ, Kohan DE, Lafayette R, Levin A, Liew A, Zhang H, Noronha IL, Mastroianni-Kirsztajn G, Chow S, Choi DE, Lv J, Trimarchi H, Fu P, Guenther S, Yang S, Liu J, Rahalkar S, Lodha A, Dahlke M, Kollins D, Barratt J; ALIGN study group. Heerspink HJL, et al. Lancet. 2026 Jun 13;407(10546):2387-2401. doi: 10.1016/S0140-6736(26)00960-8. Epub 2026 Jun 4. Lancet. 2026. PMID: 42242268 Clinical Trial.
In the main stratum, change from baseline in eGFR at week 136 was -7.5 mL/min per 1.73 m(2) (95% CI -9.2 to -5.8) with atrasentan and -9.9 mL/min per 1.73 m(2) (-11.7 to -8.1) with placebo (between-group difference 2.4 mL/min per 1.73 m(2); 95% CI -0.1 to 4.8 …
In the main stratum, change from baseline in eGFR at week 136 was -7.5 mL/min per 1.73 m(2) (95% CI -9.2 to -5.8) with atrasentan and …
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to <60 mL/min per 1.73 m(2) and 60 mL/min per 1.73 m(2)) and urine pro …
Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by es …
Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis.
Lewis JH, Korkmaz SY, Rizk CA, Copeland MJ. Lewis JH, et al. Expert Opin Drug Saf. 2024 Sep;23(9):1093-1107. doi: 10.1080/14740338.2024.2399074. Epub 2024 Sep 4. Expert Opin Drug Saf. 2024. PMID: 39212296 Review.
INTRODUCTION: Many of the first line medications for the treatment of active and latent M. tuberculosis are hepatoxic and cause a spectrum of anti-tuberculosis drug induced liver injury (ATLI), including acute liver failure (ALF). ...
INTRODUCTION: Many of the first line medications for the treatment of active and latent M. tuberculosis are hepatoxic and cause a spe …
242 results